Dr. Jeff Cao
@JeffCaoMDMBA
Followers
675
Following
5K
Media
200
Statuses
1K
Provincial Breast Lead @AHS_CancerCare | Chair @CROF_FCRO & #COLESummit | Immed Past President @albertadoctors Rad Onc Section
Calgary, Alberta
Joined August 2014
RT @drdavidpalma: This will be a great session. emerging evidence for RT for new indications 👇👇👇
0
3
0
RT @TheLancet: 🗨️ “Vaccines have done more to improve public health than any other medical intervention.”. A new Viewpoint focuses on cance….
0
458
0
RT @NEJM: In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiatio….
0
89
0
RT @JAMAOnc: For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast su….
0
46
0
RT @to_be_elizabeth: 📌 Do We "Node" What to Do About the Axilla❓.Great discussion👏🏻.✨Mediget Teshome, MD, FACS, MPH. @OncoAlert #OncoAlertA….
0
52
0
RT @Aiims1742: Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but ra….
0
66
0
RT @YukinoriOzaki: Overview of ASCO 2025 Breast Cancer topics! #ASCO25 @OncoAlert @ASCO So many important topics.
0
84
0
RT @SprakerMDPhD: A blog post on CHALLENGE and why you should be prescribing exercise today #ASCO25 . A 🧵 with some resources for you: http….
0
14
0
RT @drspdavid: 🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo).🔷 44% on same Rx….
0
28
0
RT @VivekSubbiah: 🚨 Wow! #ASCO25 @ASCO was absolutely massive!.10 @NEJM papers published simultaneously 👉 all practice-changing studies !….
0
183
0
RT @DanaFarber: .@stolaney1, MD, MPH shares interim results from the DESTINY-Breast09 study, comparing T-DXd + pertuzumab to the standard T….
0
2
0
RT @drsarahsam: Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO….
0
58
0
RT @CharlesJiangMD: So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actua….
0
49
0
RT @cwspeers: 📍For those who couldn’t make it to Chicago — here’s your front-row seat to a full day of groundbreaking breast cancer science….
0
5
0
RT @NEJM: Original Article: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (VERITAC-2 phase 3 trial) https:/….
0
7
0
RT @NEJM: Original Article: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer (INAVO120 trial) .
0
5
0